Hepatitis C Debate Should Focus on Value of Innovative Medicines

04.15.14 | By

As the debate around the cost of Hepatitis C treatment rages on, a Bloomberg article yesterday highlighted other potential Hepatitis C medicines on the horizon and the many benefits they could provide for patients living with this debilitating disease. What’s more, many of the potential new medicines might be able to offer patients fewer unwanted side effects and require less monitoring and follow-up care.

#PhRMA14: Collaborating with Patients to Advance R&D

04.15.14 | By

Collaboration was rightly a focal point of #PhRMA14 because it is incredibly important to developing new medicines. As PhRMA CEO John Castellani said at the meeting, the industry is changing rapidly and we continue to compete by “joining hands…building new strength and breadth…[and] adapting and leading.” One of the most important ways to accomplish this is by incorporating the patient into everything we do. 

Stakeholders Urge Caution in Senate Consideration of Patent Reform

04.07.14 | By

ScientistBiopharmaceutical innovation is not a given.  Strong intellectual property protections are necessary to sustain America’s role as the worldwide leader in biopharmaceutical research and are critical to the biopharmaceutical industry’s ability to make the

Taking a Long-Term View on Cost of Care

03.31.14 | By

This month, a New York Times editorial discussed the cost of a new drug to treat hepatitis C. The opinion piece took a short-term view of treating the disease, noting that a panel of experts concluded that the drug offered “low value” for treating most patients, in large part due to its cost.

State, national leaders unite to fight diabetes in South Carolina

03.26.14 | By

South Carolina StatehouseThe magnificent architecture of the South Carolina State House served as the backdrop for Diabetes under the Dome – an event obviously focusing on one of the state’s worst health nightmares: diabetes.

Collaboration is What Will Help Drive New Successes for the Rare Disease Community

03.26.14 | By

While the number of patients with any individual rare disease is relatively small, they collectively affect 1 in 10 Americans. The community successfully comes together to raise awareness on international Rare Disease Day every February, but the challenge is how to maintain the momentum – and remain united - for the remaining 364 days of the year.

CMS’ Decision a Good Call for Patients

03.20.14 | By

In January, the Centers for Medicaid and Medicare Services (CMS) issued a proposed rule that would have adversely altered Medicare Part D’s six protected classes for prescription medication, restricting Medicare beneficiary access to antidepressants and immunosuppressants beginning in 2015.

Week in Review: Putting Patients First

03.14.14 | By

This week we focused on the role of patients within the R&D process, from discovery to market access. While the industry is continually striving to create new medicines, the more that patients, stakeholders, advocates and public and private sector leaders contribute feedback, ideas and ingenuity to the research and development (R&D) process, the better the likelihood of developing the next big breakthrough that will save or improve lives.

Clinical Trial Patient Thanks Hometown Researchers

03.11.14 | By

You could have heard a pin drop as onetime clinical trial participant Laura Hull spoke at yesterday's "Research in Your Backyard" event in Winston-Salem, N.C. More than a few eyes had tears in them.

Shedding Light on an Often Overlooked Patient Population

03.11.14 | By

The recent spotlight on prescription drug abuse has overshadowed an important patient population that must deal with chronic pain everyday. Addicts, overdoses and mentions of the “opioid epidemic” in the media has made is increasingly difficult for the people who depend on these medicines to be able to get them.


Subscribe to RSS - Opinion